Point Therapeutics Announces Additions to Scientific and Clinical Advisory Boards

Point Therapeutics, Inc. (NASDAQ:POTP) announced today
the appointment of two additional advisors: Charles Dinarello, M.D.,
to the company's Scientific Advisory Board and Antonio Grillo-Lopez,
M.D. to the Clinical Advisory Board.
   Dr. Dinarello is a Professor of Medicine at the University of
Colorado School of Medicine, a member of the U.S. National Academy of
Sciences and the author of over 500 published research articles. In
addition to his active academic research career, Dr. Dinarello has
held advisory positions with two branches of the National Institutes
of Health and positions on the Board of Governors of both the Weizmann
Institute and Ben Gurion University. Dr. Dinarello is also a director
of Techne Corporation. He received his medical degree from Yale
University and clinical training at the Massachusetts General
Hospital.
   Dr. Grillo-Lopez is a consultant, clinical research and regulatory
strategist to the NCI and to several biotechnology companies. Dr.
Grillo-Lopez serves as industry representative to the Oncology Drug
Advisory Committee of the FDA. He retired in 2001 from IDEC
Pharmaceuticals, Inc. (now Biogen Idec, Inc.) where he served as chief
medical officer and senior vice president, medical and regulatory
affairs. He was the project clinician in the development of Rituxan
(the first monoclonal antibody for the treatment of cancer) and
supervised the clinical development of Zevalin (the first radiolabeled
antibody for the treatment of cancer). Prior to joining IDEC, Dr.
Grillo-Lopez held the position of executive medical director for
international clinical research and development at DuPont Merck
Pharmaceuticals He served as vice president, clinical therapeutics,
and director, clinical oncology research at Warner Lambert Company's
Parke-Davis Pharmaceutical Research Division.
   "As Point matures in the clinic, we continue to strengthen our
advisory boards. Dr. Dinarello and Dr. Lopez are welcome additions to
the team. With two Phase 3 studies underway and multiple on-going
Phase 2 studies, we appreciate the importance of experienced and
active advisory boards to support current clinical efforts and to help
develop new strategies for our technology," said Don Kiepert,
President and CEO of Point Therapeutics.

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.
In addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as a
vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development programs
and the timing of initiation and completion of its clinical trials.
Forward-looking statements are statements that are not historical
facts, and can be identified by, among other things, the use of
forward-looking language, such as "believes," "feels," "expects,"
"may," "will," "should," "seeks," "plans," "schedule to,"
"anticipates" or "intends" or the negative of those terms, or other
variations of those terms of comparable language, or by discussions of
strategy or intentions. A number of important factors could cause
actual results to differ materially from those projected or suggested
in the forward looking statement, including the risk factors described
in Point's quarterly report on Form 10-Q for the quarter ended
September 30, 2005 and from time to time in Point's periodic and other
reports filed with the Securities and Exchange Commission.